Click on the links below to preview selected pages from this course.
- Case Scenario
- Case Presentation
- Initial Serologic Test Results
- Perinatal Testing Programs
- Interpreting Initial Serologic Tests
- Interpreting Initial Serologic Tests
- Antibody Exclusion Protocol (General)
- Initial Antibody Exclusions
- Antibody Exclusion Protocols (RhIG)
- Passive or Active Immunization?
- RhIG-Derived Anti-D Reaction Strength
- Factors Affecting RhIg Reaction Strength
- How Long Can RhIG Be Detected?
- Which of the following factors is most likely to cause a false-negative antibody screen following RhIG injection?
- A pregnant female has been injected with RhIG antenatally and has a positive antibody screen at delivery. If the antibody has been confirmed as anti-D...
- A pregnant female who received RhIG at 28 weeks gestation has a positive antibody screen at delivery. If the antibody has been confirmed as anti-D alo...
- Follow-up Serologic Tests
- How Much Testing?
- Mini-Panel Antibody Exclusion
- Using the guidelines in the antibody exclusion protocol, all unexcluded antibodies (anti-C, E, K, Fyb, Jka, N, s, Lea) have been excluded by the mini-...
- Post-delivery Testing
- Serologic Tests on Newborn
- The newborn's ABO group is invalid because no reverse (serum) group was set up with A1 and B cells.
- The newborn's Rh(D) type is invalid because the DAT is positive.
- The positive DAT on the newborn means that the infant probably has clinically significant hemolysis.
- Newborn's Clinical Status
- Is the mother a candidate for RhIG? (type Y for yes or N for no)
- Screening for Fetomaternal Hemorrhage (FMH)
- Quantifying FMH
- Kleihauer-Betke (KB) Test
- Flow Cytometry
- Calculating RhIG Dosage
- Assessing FMH and RhIG Dosage
- Which of the following tests are suitable for quantifying the size of fetomaternal hemorrhage (FMH)? Select all that apply.
- Facilities that use a special calculation for RhIG dosage add one vial, regardless if they round up or round down.
- Summary and Conclusions
- When Transfusion Is Necessary
- Further Reading
Level of instruction: Intermediate
Intended Audience: Clinical laboratory technologists, technicians, and pathologists. This course is also appropriate for clinical laboratory science students and pathology residents.
: Pat Letendre, MEd is a laboratory technologist, educator, and consultant. Currently, she consults full-time in the areas of transfusion medicine, education, professional development, and use of the Internet in education. Ms. Letendre is the Webmaster for Canada's transfusion safety officers and the TraQ website coordinator. She holds a Masters of Education degree in adult education from the University
and a Bachelor of Science degree from the University of Manitoba
Reviewer information: Erin Tretter, MT(ASCP), is currently the STAT Laboratory Supervisor at Penn Presbyterian Medical Center in Philadelphia, PA. She received her BS in Medical Technology from California University of Pennsylvania and has nearly 8 years of experience as a Generalist, including Blood Bank, Hematology and Chemistry. Erin is the Blood Bank Clinical Instructor for the Clinical Laboratory Science Program at St. Christopher’s and has 4 years experience teaching immunohematology concepts and laboratory procedures to Medical Technology students. She has also provided blood bank training for laboratory technologists and medical students. Erin is currently obtaining a Master’s in Business Administration from Florida Institute of Technology where she is a member of the Phi Kappa Phi Honor’s Society.
Rory Huschka, M. Ed., MT(ASCP), has over 20 years of combined experience as a medical technologist, technical supervisor, professor, and manager. He is the former Director of Clinical Laboratory Science and Medical Laboratory Technician Programs at Brookline College. He is currently a Program Director at MediaLab, Inc. Rory holds a BS degree in Medical Technology from North Dakota State University and a Masters in Educational Leadership.